MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Puma Biotechnology, Inc.

< Previous 1 2 3 4 Next >
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket’ Trial of Neratinib at the ASCO 2022 Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports First Quarter 2022 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Releases Updated Corporate Presentation
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Present at the H.C. Wainwright BioConnect Conference
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Third Quarter 2021 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Second Quarter 2021 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story